Bronchiolitis

Chapter 53


image


Bronchiolitis


Girish D. Sharma, MD, FCCP


Introduction/Etiology/Epidemiology


Bronchiolitis is a lower respiratory tract viral infection in infants, characterized by acute inflammation, edema, necrosis of the epithelial lining of the small airways, and mucus production.


Bronchiolitis is the most common cause of hospital admission among infants during the first 12 months of life.


In the United States, 2%–3% of infants younger than 12 months are hospitalized with a diagnosis of bronchiolitis.


Bronchiolitis is most commonly caused by respiratory syncytial virus (RSV) (50%–80%), followed by human rhinovirus (5%–25%), parainfluenza, human metapneumovirus, coronavirus, adenovirus, influenza, and enterovirus.


Bronchiolitis occurs most commonly from November to March in the United States, with some regional variation; human rhinovirus RSV occurs most commonly in the spring and fall.


Ninety percent of children are infected with RSV in the first 2 years of life; ≤40% have signs and symptoms of lower respiratory tract infection during the initial infection.


Clinical Features


In a typical case, after an incubation period of 4–6 days (range, 2–8 days), upper respiratory infection symptoms develop with irritability and poor feeding.


Bronchiolitis typically begins as an upper respiratory infection with rhinorrhea, congestion, and cough, which may progress to tachypnea, grunting, wheeze, inspiratory crackles, rales, use of accessory muscles with retractions, and nasal flaring.


Patients with more severe disease and respiratory distress may develop feeding with interruptions, reduced oral intake, dehydration, apnea, and respiratory failure.


Risk factors include age <12 weeks, history of prematurity, underlying cardiopulmonary disease, immunodeficiency, and low concentration of maternal antibodies.


Babies with low ex vivo interferon-γ responses in early life are more likely to have frequent viral respiratory infections, including those associated with wheeze.


The disease course is variable and dynamic, ranging from transient events, such as apnea, to prolonged respiratory distress and respiratory failure.


Bronchiolitis is likely to be more severe in the presence of chronic lung disease of prematurity, in infants born before 29 weeks, and in the presence of certain types of hemodynamically important congenital heart disease with pulmonary hypertension or congestive heart failure. Other factors include chronic lung disease caused by cystic fibrosis and Down syndrome and perinatal environmental smoke exposure.


Twenty-five percent to 50% of patients who receive a diagnosis of bronchiolitis have similar recurrent symptoms, in the form of viral infection–associated wheeze.


RSV bronchiolitis has been correlated with subsequent development of wheeze and asthma, and recent findings from the “COAST” (Childhood Origins of Asthma) study suggest that early rhinovirus illnesses are a more robust predictor of subsequent development of asthma in high-risk children.


Diagnostic Considerations


American Academy of Pediatrics (AAP) clinical practice guidelines indicate that physicians should diagnose bronchiolitis and assess the disease severity on the basis of history and physical examination findings.


The guidelines do not advocate the use of radiographic or laboratory studies routinely.


Antigen testing of nasal washings, respiratory viral panel, and viral cultures is not routinely recommended.


Management


Supportive management consists of oxygen supplementation when oxygen saturation at pulse oximetry (SpO2) is <90%, with intravenous or nasogastric fluids administered to children with inadequate oral intake.


AAP clinical practice guidelines do not recommend the administration of nebulized hypertonic saline in the emergency department or the administration of albuterol, epinephrine, or systemic steroids.


Use of continuous pulse oximetry, chest physical therapy, and antibiotics (unless there is concomitant bacterial infection or strong suspicion) is not recommended by AAP guidelines.


The physician may choose not to administer oxygen supplementation if the oxyhemoglobin saturation exceeds 90%.


Prevention


Palivizumab should be given during the first year of life to infants with hemodynamically significant heart disease, chronic lung disease, or prematurity (preterm infants <32 weeks’ gestation who require >21% oxygen for at least the first 28 days after birth).


Palivizumab prophylaxis may be administered to preterm infants born before 29 weeks’ gestation who are <12 months of age at the start of the RSV season.


A maximum of 5 monthly doses (15 mg/kg per dose) should be given during the RSV season for the infants that qualify for its administration.


Use alcohol-based disinfectant hand rubs or perform thorough handwashing with soap and water before and after direct contact with the patient, after contact with inanimate objects in the direct vicinity of the patient, and after removing gloves.


Counsel parents about the harmful effects of tobacco smoke exposure and advise smoking cessation.


Encourage breastfeeding.


Educate medical personnel and family members on appropriate evidence-based diagnosis, treatment, and prevention of bronchiolitis.


Prognosis


The prognosis is usually self-limited, with a high degree of morbidity and a low mortality rate.


Up to 60% of patients may develop acute otitis media.


The presence of apnea, respiratory distress, respiratory failure, poor oral intake and resultant dehydration, and inability of the caretaker to monitor the infant may warrant hospitalization.


Reported rare complications include myocarditis, arrhythmia, complete heart block, sepsis-like syndrome, seizures, focal neurological deficits, and hepatitis.


Some patients develop asthma subsequent to human rhinovirus bronchiolitis.


The mortality rate is ≤2.0 per 100,000 live births, with most deaths occurring in the 1–3-month-old age group; risk factors are low birth weight, increasing birth order, low 5-minute Apgar score, young maternal age, unmarried mother, and tobacco use during pregnancy.


For patients with RSV bronchiolitis who are admitted to the pediatric intensive care unit, a mortality rate of 2%–7% has been reported.


Reported long-term sequelae after severe bronchiolitis include bronchiolitis obliterans, allergic sensitization, wheeze, and asthma.


When to Refer


Poor oral intake; dehydration; low oxyhemoglobin saturation (SpO2 <90%); inability of the caretaker to monitor the patient; presence of complications, such as marked respiratory distress and apnea; and signs of respiratory failure are indications for referral.


The presence of risk factors for severe disease, such as age <12 weeks, history of prematurity, underlying cardiopulmonary disease, or immunodeficiency, are indications for referral.


Uncertain diagnosis, a need for prolonged oxygen supplement, and the need for frequent hospitalizations warrant referral to a pediatric pulmonologist.


Resources for Families


Bronchiolitis (American Academy of Pediatrics). www.healthychildren.org/English/health-issues/conditions/chest-lungs/Pages/Bronchiolitis.aspx


Bronchiolitis and Your Child (American Academy of Family Physicians). www.aafp.org/afp/2001/0215/p767.html


Bronchiolitis – Discharge (Medline Plus). medlineplus.gov/ency/ patientinstructions/000007.htm



 


Section 2. Parenchymal Infections


Chapter 54: Bacterial Pneumonia


Paul C. Stillwell, MD, FAAP


Chapter 55: Viral Pneumonia


Paul C. Stillwell, MD, FAAP


Chapter 56: Mycoplasma Pneumonia


Oren Kupfer, MD


Paul C. Stillwell, MD, FAAP


Chapter 57: Chlamydial Pneumonia


Paul C. Stillwell, MD, FAAP


Chapter 58: Tuberculosis


Carol Conrad, MD


Chapter 59: Nontuberculous Mycobacterial Pulmonary Disease


Paul C. Stillwell, MD, FAAP


Stacey Martiniano, MD


Chapter 60: Fungal Pneumonia


Paul C. Stillwell, MD, FAAP


Chapter 61: Histoplasmosis and Other Endemic Fungal Pneumonias


Paul C. Stillwell, MD, FAAP


Chapter 62: Complications of Pneumonia: Pleural Effusions


Oren Kupfer, MD


Paul C. Stillwell, MD, FAAP


Chapter 63: Pneumonia Complications: Empyema


Oren Kupfer, MD


Paul C. Stillwell, MD, FAAP


Chapter 64: Complications of Pneumonia: Pulmonary Abscess


Oren Kupfer, MD


Paul C. Stillwell, MD, FAAP


Chapter 65: Complications of Pneumonia: Postinfective Bronchiolitis Obliterans


Paul C. Stillwell, MD, FAAP


Deborah R. Liptzin, MD, MS, FAAP

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Aug 8, 2019 | Posted by in PEDIATRICS | Comments Off on Bronchiolitis

Full access? Get Clinical Tree

Get Clinical Tree app for offline access